Annual SGA
$292.24 M
+$72.54 M+33.02%
December 31, 2023
Summary
- As of February 7, 2025, RVNC annual SGA is $292.24 million, with the most recent change of +$72.54 million (+33.02%) on December 31, 2023.
- During the last 3 years, RVNC annual SGA has risen by +$140.39 million (+92.46%).
- RVNC annual SGA is now at all-time high.
Performance
RVNC SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly SGA
$62.22 M
-$3.12 M-4.78%
September 30, 2024
Summary
- As of February 7, 2025, RVNC quarterly SGA is $62.22 million, with the most recent change of -$3.12 million (-4.78%) on September 30, 2024.
- Over the past year, RVNC quarterly SGA has dropped by -$2.94 million (-4.51%).
- RVNC quarterly SGA is now -33.48% below its all-time high of $93.53 million, reached on December 31, 2023.
Performance
RVNC Quarterly SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM SGA
-$8.59 B
-$184.44 M-2.20%
September 30, 2024
Summary
- As of February 7, 2025, RVNC TTM SGA is -$8.59 billion, with the most recent change of -$184.44 million (-2.20%) on September 30, 2024.
- Over the past year, RVNC TTM SGA has dropped by -$8.85 billion (-3339.51%).
- RVNC TTM SGA is now -3832.63% below its all-time high of -$218.33 million.
Performance
RVNC TTM SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Selling, General & Administrative Expenses Formula
SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development
RVNC Selling, General & Administrative Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +33.0% | -4.5% | -3339.5% |
| 3 y3 years | +92.5% | +20.2% | -4319.0% |
| 5 y5 years | +442.6% | +277.2% | -10000.0% |
RVNC Selling, General & Administrative Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +47.0% | -33.5% | +41.6% | -65.7% | at low |
| 5 y | 5-year | at high | +371.3% | -33.5% | +220.8% | -175.1% | at low |
| alltime | all time | at high | +5160.8% | -33.5% | +3754.9% | -3832.6% | at low |
Revance Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $62.22 M(-4.8%) | $290.00 M(-1.0%) |
| Jun 2024 | - | $65.34 M(-5.2%) | $292.94 M(-2.8%) |
| Mar 2024 | - | $68.91 M(-26.3%) | $301.37 M(+2.4%) |
| Dec 2023 | $292.24 M(+33.0%) | $93.53 M(+43.5%) | $294.38 M(+11.1%) |
| Sep 2023 | - | $65.16 M(-11.7%) | $265.04 M(+0.2%) |
| Jun 2023 | - | $73.77 M(+19.1%) | $264.62 M(+11.3%) |
| Mar 2023 | - | $61.92 M(-3.5%) | $237.68 M(+8.2%) |
| Dec 2022 | $219.70 M(+10.5%) | $64.19 M(-0.8%) | $219.70 M(+7.3%) |
| Sep 2022 | - | $64.74 M(+38.2%) | $204.81 M(+6.8%) |
| Jun 2022 | - | $46.83 M(+6.6%) | $191.84 M(-1.5%) |
| Mar 2022 | - | $43.94 M(-10.9%) | $194.69 M(-2.1%) |
| Dec 2021 | $198.82 M(+30.9%) | $49.30 M(-4.8%) | $198.82 M(-2.3%) |
| Sep 2021 | - | $51.77 M(+4.2%) | $203.51 M(+2.1%) |
| Jun 2021 | - | $49.68 M(+3.3%) | $199.25 M(+11.3%) |
| Mar 2021 | - | $48.07 M(-10.9%) | $178.94 M(+17.8%) |
| Dec 2020 | $151.85 M(+144.9%) | $53.98 M(+13.6%) | $151.85 M(+29.5%) |
| Sep 2020 | - | $47.51 M(+61.8%) | $117.26 M(+36.0%) |
| Jun 2020 | - | $29.37 M(+40.0%) | $86.24 M(+22.4%) |
| Mar 2020 | - | $20.98 M(+8.2%) | $70.47 M(+12.9%) |
| Dec 2019 | $62.01 M(+15.1%) | $19.39 M(+17.6%) | $62.40 M(+10.7%) |
| Sep 2019 | - | $16.50 M(+21.3%) | $56.36 M(+4.3%) |
| Jun 2019 | - | $13.60 M(+5.3%) | $54.02 M(+1.6%) |
| Mar 2019 | - | $12.91 M(-3.4%) | $53.16 M(-1.3%) |
| Dec 2018 | $53.86 M | $13.36 M(-5.6%) | $53.86 M(+2.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | $14.15 M(+11.2%) | $52.39 M(+10.6%) |
| Jun 2018 | - | $12.73 M(-6.5%) | $47.38 M(+9.5%) |
| Mar 2018 | - | $13.62 M(+14.5%) | $43.26 M(+15.7%) |
| Dec 2017 | $37.40 M(+28.6%) | $11.89 M(+29.9%) | $37.40 M(+14.7%) |
| Sep 2017 | - | $9.15 M(+6.3%) | $32.61 M(+5.3%) |
| Jun 2017 | - | $8.61 M(+11.0%) | $30.96 M(+5.4%) |
| Mar 2017 | - | $7.75 M(+9.2%) | $29.37 M(+1.0%) |
| Dec 2016 | $29.07 M(+15.9%) | $7.10 M(-5.4%) | $29.07 M(+0.7%) |
| Sep 2016 | - | $7.50 M(+6.9%) | $28.88 M(+6.2%) |
| Jun 2016 | - | $7.02 M(-5.9%) | $27.20 M(+2.5%) |
| Mar 2016 | - | $7.46 M(+8.0%) | $26.55 M(+5.8%) |
| Dec 2015 | $25.09 M(+31.7%) | $6.91 M(+18.5%) | $25.09 M(+9.2%) |
| Sep 2015 | - | $5.83 M(-8.4%) | $22.98 M(+2.3%) |
| Jun 2015 | - | $6.36 M(+6.1%) | $22.45 M(+7.2%) |
| Mar 2015 | - | $6.00 M(+25.1%) | $20.95 M(+10.0%) |
| Dec 2014 | $19.04 M(+72.9%) | $4.79 M(-9.6%) | $19.04 M(+10.4%) |
| Sep 2014 | - | $5.30 M(+9.1%) | $17.25 M(+22.4%) |
| Jun 2014 | - | $4.86 M(+18.7%) | $14.10 M(+9.4%) |
| Mar 2014 | - | $4.09 M(+36.3%) | $12.88 M(+17.0%) |
| Dec 2013 | $11.01 M(-1.6%) | $3.00 M(+40.2%) | $11.01 M(+14.4%) |
| Sep 2013 | - | $2.14 M(-41.2%) | $9.62 M(+28.6%) |
| Jun 2013 | - | $3.64 M(+63.6%) | $7.48 M(+94.8%) |
| Mar 2013 | - | $2.23 M(+37.9%) | $3.84 M(+137.9%) |
| Dec 2012 | $11.20 M(+101.5%) | $1.61 M | $1.61 M |
| Dec 2011 | $5.55 M | - | - |
FAQ
- What is Revance Therapeutics annual SGA?
- What is the all time high annual SGA for Revance Therapeutics?
- What is Revance Therapeutics annual SGA year-on-year change?
- What is Revance Therapeutics quarterly SGA?
- What is the all time high quarterly SGA for Revance Therapeutics?
- What is Revance Therapeutics quarterly SGA year-on-year change?
- What is Revance Therapeutics TTM SGA?
- What is the all time high TTM SGA for Revance Therapeutics?
- What is Revance Therapeutics TTM SGA year-on-year change?
What is Revance Therapeutics annual SGA?
The current annual SGA of RVNC is $292.24 M
What is the all time high annual SGA for Revance Therapeutics?
Revance Therapeutics all-time high annual SGA is $292.24 M
What is Revance Therapeutics annual SGA year-on-year change?
Over the past year, RVNC annual SGA has changed by +$72.54 M (+33.02%)
What is Revance Therapeutics quarterly SGA?
The current quarterly SGA of RVNC is $62.22 M
What is the all time high quarterly SGA for Revance Therapeutics?
Revance Therapeutics all-time high quarterly SGA is $93.53 M
What is Revance Therapeutics quarterly SGA year-on-year change?
Over the past year, RVNC quarterly SGA has changed by -$2.94 M (-4.51%)
What is Revance Therapeutics TTM SGA?
The current TTM SGA of RVNC is -$8.59 B
What is the all time high TTM SGA for Revance Therapeutics?
Revance Therapeutics all-time high TTM SGA is -$218.33 M
What is Revance Therapeutics TTM SGA year-on-year change?
Over the past year, RVNC TTM SGA has changed by -$8.85 B (-3339.51%)